tradingkey.logo

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study Of Once-Daily Alixorexton IN PATIENTS WITH NARCOLEPSY TYPE 1

ReutersJul 21, 2025 10:10 AM

- Alkermes Plc ALKS.O:

  • ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM VIBRANCE-1 PHASE 2 STUDY OF ONCE-DAILY ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1

  • ALKERMES PLC - ALIXOREXTON SHOWS SIGNIFICANT IMPROVEMENTS IN WAKEFULNESS IN NT1

  • ALKERMES PLC - ALIXOREXTON GENERALLY WELL TOLERATED AT ALL DOSES

  • ALKERMES PLC - ALIXOREXTON ADVANCING TO PHASE 3 DEVELOPMENT IN NARCOLEPSY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI